Human CD22 Monoclonal Antibody
Produktgrößen
1 mg
£486,00
YR0113-1MG
5 mg
£1355,00
YR0113-5MG
20 mg
£3531,00
YR0113-20MG
Über dieses Produkt
- SKU:
- YR0113
- Zusätzliche Namen:
- SIGLEC-2|SIGLEC2
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human CD22
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0113